Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03967223 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03967223 · ClinicalTrials.gov record · last posted 2026-08-11

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Name: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — clinical trial record (NCT03967223)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: IGNYTE-ESO

StatusActive, Not Recruiting

PhasePhase 2

SponsorUSWM CT, LLC

Started2019-12-31

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.

Protocol amendment history 1 change detected by DataLookout

2026-08-12

Completion pushed: 2026-07-31 → 2028-07-31

Trial Details

NCT Number	NCT03967223
Lead Sponsor	USWM CT, LLC
Conditions	Neoplasms
Enrollment	103 participants
Start Date	2019-12-31
Primary Completion	2024-03-01 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-11